Introduction Of A Polynucleotide Molecule Into Or Rearrangement Of Nucleic Acid Within An Animal Cell Patents (Class 435/455)
  • Patent number: 11102961
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: August 31, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
  • Patent number: 11078494
    Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: August 3, 2021
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Gordon Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans J. Fehling
  • Patent number: 11045584
    Abstract: A process for producing a bone construct, including the steps of providing a perfusion bioreactor having an inlet and an outlet; providing the perfusion bioreactor with a seeded scaffold comprising a porous scaffold seeded with mesenchymal stem cells; continuously perfusing the seeded scaffold with an osteogenic induction (differentiation) media; measuring dissolved oxygen content of the osteogenic induction media at the inlet and at the outlet to determine an oxygen uptake rate (OUR) for the seeded scaffold; measuring glucose content of the osteogenic induction media to determine a glucose consumption rate (GCR) for the seeded scaffold; and removing the seeded scaffold from the perfusion reactor as a bone construct after the ratio of the OUR to the GCR (OUR/GCR) has been determined to exceed a predetermined threshold OUR/GCR value.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: June 29, 2021
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Vassilios Sikavitsas, Aaron D. Simmons
  • Patent number: 11030531
    Abstract: The invention provides, inter alia, recombinase-based systems that provide for integrated logic and memory in living cells such as mammalian cells. The nucleic acid cassettes, switches, and systems described herein allow for control of gene expression or gene regulation. The invention also provides nucleic acid-based switches for adopted T-cell therapy.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: June 8, 2021
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Wilson W. Wong, Benjamin Harris Weinberg
  • Patent number: 11015204
    Abstract: This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5? UTRs, where a 5? UTR may be expressed by a gene of a plant. In some embodiments, a 5? UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: May 25, 2021
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Pattraranee Limphong, Carlos G. Perez-Garcia, Kiyoshi Tachikawa, Padmanabh Chivukula, Arisa Cale, Angel I-Jou Leu, Jared Davis
  • Patent number: 11001809
    Abstract: Disclosed herein are methods of generating induced pluripotent stem cells. The method involves providing a quantity of somatic or non-embryonic cells, contacting the contacting the somatic or non-embryonic cells with a quantity of one or more reprogramming factors and one or more RNA molecules, and culturing the somatic or non-embryonic cells for a period of time sufficient to generate at least one induced pluripotent stem cell. Various reprogramming factors and RNA molecules for use in the methods are disclosed herein. Also disclosed are cell lines and pharmaceutical compositions generated by use of the methods.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: May 11, 2021
    Assignee: The McLean Hospital Corporation
    Inventors: Kwang-Soo Kim, Young Cha
  • Patent number: 10975136
    Abstract: The present invention relates to the field of genetic engineering, in particular, to a transposon-based transfection kit suitable for transfection of primary cells, such as T cells, comprising mRNA encoding a transposase, or reagents for generating mRNA encoding said transposase, as well as minicircle DNA comprising the transposon. The invention also relates to a nucleic acid, preferably, a DNA minicircle, comprising a transposon, wherein the transposon encodes a protein and at least one miRNA, wherein the sequences encoding the miRNA are located in an intron and expression of the protein and the miRNA is regulated by the same promoter. The invention also provides a population of cells obtainable with the method of the invention. Methods of transfection are also provided, as well as medical use, e.g. in immunotherapy, in particular, in adoptive T cell therapy or T cell receptor (TCR) or chimeric antigen receptor (CAR) gene therapy.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: April 13, 2021
    Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
    Inventors: Wolfgang Uckert, Mario Bunse, Julian Clauss, Zsuzsanna Izsvák
  • Patent number: 10959413
    Abstract: A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: March 30, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Luhan Yang, Marc Guell
  • Patent number: 10923490
    Abstract: A semiconductor memory device includes a semiconductor substrate, a first insulating film provided above the semiconductor substrate, a first conductive film provided above the first insulating film, a plurality of first electrode films provided above the first conductive film and stacked to be separated from each other, a semiconductor member extending in a stacking direction of the plurality of first electrode films, and a charge storage member provided between the semiconductor member and one of the plurality of first electrode films. The first conductive film includes a main portion disposed at least below the plurality of first electrode films, and a fine line portion extending from the main portion toward an end surface side of the semiconductor substrate. A width of the fine line portion is narrower than a width of the main portion.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: February 16, 2021
    Assignee: Toshiba Memory Corporation
    Inventors: Kotaro Fujii, Jun Fujiki, Shinya Arai
  • Patent number: 10888589
    Abstract: Methods and compositions for modifying stem cells using one or more ZFPs are disclosed. Such methods and compositions are useful for facilitating processes such as, for example, dedifferentiating cells, differentiating stem cells into the desired phenotype, propagating stem cells and/or facilitating cloning.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Alan P. Wolffe, Michael Moore, Timothy Farries, Trevor Collingwood, Fyodor Urnov
  • Patent number: 10889834
    Abstract: Disclosed herein are methods and compositions for enhancing insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease or a hemophilia by administering one or more topoisomerases inhibitors, one or more stabilizers of R loop formation or inhibitors of R-loop repair and/or one or more up-regulators of the TC-NER pathway to the target cell.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 12, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Thomas Wechsler
  • Patent number: 10876126
    Abstract: This invention provides methods for producing a non-natural hybrid seed. Also disclosed are specific miRNAs and miRNA recognition sites useful for conferring inducible sterility on a crop plant, and recombinant DNA construct including such exogenous miRNA recognition sites.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: December 29, 2020
    Assignee: Monsanto Technology LLC
    Inventors: Edwards Allen, Larry A. Gilbertson, James K. Roberts, Nancy M. Houmard, Shihshieh Huang, Sergey Ivashuta
  • Patent number: 10858357
    Abstract: The present invention relates to highly soluble, non-fluorescent and photostable myosin inhibitors; especially, for in vivo inhibition of the ATPase activity of neuronal non-muscle myosin 2 of formula (II): wherein Q1, Q2, Q3, Q4, R1, R2, R4 and R5 are as defined in claim 1. The invention also relates to pharmaceutical compositions or medicaments comprising the compounds of the invention and processes for manufacturing these compounds and their intermediates.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: December 8, 2020
    Assignees: PARIS SCIENCES ET LETTRES-QUARTIER LATIN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), PRINTNET LTD.
    Inventors: Zsolt Lenkei, András Málnási Csizmadia, Miklós Képiró, Boglárka Várkuti
  • Patent number: 10849981
    Abstract: The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: December 1, 2020
    Assignee: KemPham, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 10793620
    Abstract: The invention refers to a non-therapeutic method for producing antigen-specific B cells by using the adoptive cell transfer of primed B cells, especially of spleen cells including B cells of a previously immunized non-human animal and by administering an antigen of interest to a naïve non-human animal.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: October 6, 2020
    Assignee: BIOGENES GMBH
    Inventor: Detlef Schmechel
  • Patent number: 10787662
    Abstract: Provided herein are methods and compositions to make guide nucleic acids (gNAs), nucleic acids encoding gNAs, collections of gNAs, and nucleic acids encoding for a collection of gNAs from any source nucleic acid. Also provided herein are methods and compositions to use the resulting gNAs, nucleic acids encoding gNAs, collections of gNAs, and nucleic acids encoding for a collection of gNAs in a variety of applications.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: September 29, 2020
    Assignee: ARC BIO, LLC
    Inventor: Stephane B. Gourguechon
  • Patent number: 10787523
    Abstract: Various embodiments disclosed relate to a nanoparticle-protein complex for intracellular protein delivery. In various embodiments, the present invention provides a nanoparticle-protein complex including a nanoparticle including an amine-containing ligand. The nanoparticle-protein complex also includes a protein comprising a carboxylic acid-containing tag.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: September 29, 2020
    Assignee: University of Massachusetts
    Inventors: Vincent M. Rotello, Rubul Mout
  • Patent number: 10782304
    Abstract: The present invention relates to methods and kits for detection protein-protein interactions.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: September 22, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PAUL SABATIER TOULOUSE III
    Inventors: Stéphanie Cabantous, Faten Koraïchi, Gilles Favre
  • Patent number: 10765758
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 8, 2020
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • Patent number: 10745692
    Abstract: An object of the present invention is to provide a method of producing a peptide containing a charged non-proteinogenic amino acid in a cell-free translation system, and the like. The present invention provides a method of producing a peptide containing a charged non-proteinogenic amino acid. It includes a step of expressing a peptide in a cell-free translation system including (i) at least one tRNA to which a non-proteinogenic amino acid having a protecting-group-introduced charged group has been bound and (ii) a nucleic acid that encodes the peptide and contains at least one codon corresponding to an anticodon of the tRNA; and a step of removing the protecting group of the non-proteinogenic amino acid residue contained in the peptide.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: August 18, 2020
    Assignees: The University of Tokyo, PeptiDream Inc.
    Inventors: Hiroshi Murakami, Takashi Kawakami, Patrick Reid, Toru Sasaki
  • Patent number: 10745716
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: August 18, 2020
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Fuqiang Chen, Gregory D. Davis
  • Patent number: 10731181
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: August 4, 2020
    Assignee: Sigma, Aldrich Co. LLC
    Inventors: Fuqiang Chen, Gregory D. Davis
  • Patent number: 10724005
    Abstract: Disclosed herein are methods of producing chondrocytes from pluripotent stem cells. The invention further provides methods of regenerating cartilaginous tissue.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: July 28, 2020
    Assignee: SCRIPPS HEALTH
    Inventors: Darryl D. D'Lima, Tsaiwei Olee, Clifford W. Colwell
  • Patent number: 10724010
    Abstract: The present disclosure relates to recombinantly engineered cells that contain a chlorite dismutase polypeptide and methods for culturing such cells in a culture medium containing chlorite in an amount sufficient to reduce the growth rate or kill contaminating microorganisms without killing the recombinantly engineered cells. Also provided are methods for the production of a fermentation product using the recombinantly engineered cells.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: July 28, 2020
    Assignee: The Regents of the Uniiversity of California
    Inventor: John D. Coates
  • Patent number: 10709761
    Abstract: The present disclosure is directed to methods and compositions for inhibiting a cancer cell using nucleic acid sequences encoding elephant p53 or elephant p53 amino acid sequences.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: July 14, 2020
    Assignees: UNIVERSITY OF UTAH RESEARCH FOUNDATION, TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Joshua Schiffman, Avi Schroeder, Lisa Abegglen
  • Patent number: 10683490
    Abstract: Methods of making mutant Cas9 proteins are described.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: June 16, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Alejandro Chavez, Frank J. Poelwijk, George M. Church
  • Patent number: 10654918
    Abstract: Anti-cytokine therapy has revolutionized immunological disease treatment, but is not always effective and subject to treatment resistance as the cytokine cascade is highly redundant and multiple cytokines are involved in inflammation. Targeting a critical common regulator of inflammatory effectors is desirable. Lipopolysaccharide (LPS)-responsive beige-like anchor (LRBA) is a master regulator of multiple genes important for inflammation. Subcellular localization shows that LRBA translocated to the nucleus upon LPS stimulation and colocalized with multiple proteins associated with the endosome membrane system, indicating a critical role in membrane/vesicle trafficking essential for deposition, secretion and signal transduction of immune effectors.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: May 19, 2020
    Assignee: University of South Florida
    Inventors: Jia-Wang Wang, Richard F. Lockey
  • Patent number: 10647963
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: May 12, 2020
    Assignee: TILT BIOTHERAPEUTICS OY
    Inventors: Akseli Hemminki, Markus Vaha-Koskela, Siri Tahtinen, Vincenzo Cerullo
  • Patent number: 10624851
    Abstract: The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: April 21, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
    Inventor: Saul Yedgar
  • Patent number: 10612030
    Abstract: Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: April 7, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Zhi-Ying Chen
  • Patent number: 10583084
    Abstract: There are provided liposomes, comprising cationic lipids, a membrane stabilizing lipid and at least one lipid conjugated to a polyethylene glycol (PEG) derivative, in particular PEG-amine, the liposomes are coated with a glycosaminoglycan, in particular, Hyaluronic Acid (HA), compositions comprising the same, methods for their preparation and uses thereof for the efficient delivery of nucleic acids, such as, si RNA molecules and for treating various conditions, such as cancer.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: March 10, 2020
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventor: Dan Peer
  • Patent number: 10570418
    Abstract: The present disclosure provides compositions and methods of site-specific modification of a target DNA, or a protein associated with a target DNA, in a eukaryotic cell. The present disclosure provides methods of binding a target DNA in a eukaryotic cell.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: February 25, 2020
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Steven Lin, Brett T. Staahl
  • Patent number: 10563225
    Abstract: Methods are provided for the use of Cas9 in genome engineering of stem cells. Methods include introducing into the stem cell a first foreign nucleic acid encoding a guide RNA complementary to a target DNA and which guides a Cas9 enzyme to the target DNA, wherein the RNA and the enzyme are members of a co-localization complex for the target DNA, introducing into the stem cell a second foreign nucleic acid encoding a donor nucleic acid sequence, wherein the guide RNA and the donor nucleic acid sequences are expressed, wherein the guide RNA and the Cas 9 enzyme co-localize to the target DNA, the Cas 9 enzyme cleaves the target DNA and the donor nucleic acid is inserted into the target DNA to produce altered DNA in the stem cell.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: February 18, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Luhan Yang, Marc Guell, Joyce Lichi Yang
  • Patent number: 10555910
    Abstract: Methods for inhibiting oligonucleotide activity in vitro or in vivo to a cell that are formulated with at least one oligonucleotide encapsulated in a lipid nanoparticle are disclosed.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: February 11, 2020
    Assignee: Ohio State Innovation Foundation
    Inventor: Robert J. Lee
  • Patent number: 10538560
    Abstract: The present disclosure provides opsins, including variant opsins with increased activity and/or increased trafficking to the plasma membrane. The opsins are useful in therapeutic and screening applications, which are also provided.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: January 21, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Feng Zhang, Viviana Gradinaru
  • Patent number: 10517896
    Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: December 31, 2019
    Assignee: CELLECTIS
    Inventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
  • Patent number: 10507237
    Abstract: The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: December 17, 2019
    Assignee: The Pirbright Institute
    Inventors: Charles Abrams, Ana-Luisa Reis, Chris Netherton, Linda Dixon, Dave Chapman, Pedro Sanchez-Cordon
  • Patent number: 10501759
    Abstract: The present invention provides methods and compositions for improving the efficacy of viral transduction of cells. More particularly, the present invention provides methods and materials useful for safely and reliably improving the efficiency of methods for transducing cells, such as human hematopoietic stem cells (HSC), with viruses and/or viral vectors. The compositions and methods are useful for therapeutic indications amenable to treatment with hematopoietic stem cell gene therapies.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: December 10, 2019
    Assignee: BLUEBIRD BIO, INC.
    Inventors: Garrett Collins Heffner, Abraham Isaac Bassan
  • Patent number: 10495645
    Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: December 3, 2019
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Sarah K. C. Cheung, Po-Kai Chuang, Tsui-Ling Hsu
  • Patent number: 10443051
    Abstract: A method for performing homologous recombination between at least a first nucleic acid molecule and a second nucleic acid molecule which share at least one region of sequence homology. A method for improving the efficiency of homologous recombination.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: October 15, 2019
    Assignee: GENE BRIDGES GMBH
    Inventors: Youming Zhang, Jun Fu, Adrian Francis Stewart
  • Patent number: 10429288
    Abstract: Provided herein are methods to characterize preparations of recombinant viral particles using analytical ultracentrifugation. Recombinant viral particles include recombinant adeno-associated viral particles, recombinant adenoviral particles, recombinant lentiviral particles and recombinant herpes simplex virus particles. Variant species of recombinant viral particles including empty capsids and recombinant viral particles with variant genomes (e.g., truncated genomes, aggregates, recombinants) can be identified and quantitated. The methods can be used to characterize preparations of recombinant viral particles regardless of the sequence of the recombinant viral genome or the serotype of the recombinant viral capsid.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: October 1, 2019
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, Brenda Burnham
  • Patent number: 10428141
    Abstract: Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: October 1, 2019
    Assignees: LENTIGEN TECHNOLOGY, INC., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Patent number: 10415022
    Abstract: The present invention is directed to nucleic acid and amino acid sequences of a novel piggyBac transposase enzymes created by modifying the transposase of Trichoplusia ni. The piggyBac transposases of the present invention are functionally active or hyperactive for excision and have decreased integration activity compared to wild type Trichoplusia ni piggyBac transposase enzyme. These transposases are ideal for use in methods of transforming cells and organisms. In particular embodiments, the present invention provides methods of transient integration and expression of transgenes.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: September 17, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventor: Nancy L. Craig
  • Patent number: 10370452
    Abstract: The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and/or expandable T cells from pluripotent stem cells engineered through safe genetic modifications. The engineered cells may provide one or more of: 1) targeting a specific predetermined antigen expressed on the cell surface of a target cell in an HLA independent manner, 2) enhanced survival and functional potential 3) “off-the-shelf” T cells for administration to multiple recipients, eventually across immunogenic barriers, and/or 4) cytotoxic potential and anti-tumor activity.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: August 6, 2019
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Maria Themeli, Michel Sadelain, Christopher C. Kloss
  • Patent number: 10363321
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: July 30, 2019
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10363343
    Abstract: Disclosed herein are tissue-based drain manifolds comprising partially or completely decellularized tissue that has been processed to form tubes, columns, sheets, or other shapes and which are useful for managing the drainage of fluid and/or the administration of negative pressure at an implant site in a patient. The manifolds can be implanted in a patient and provide a natural scaffold in which native cells from surrounding tissue can migrate and proliferate, thereby avoiding the need to remove the implanted manifolds after drainage is complete.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: July 30, 2019
    Assignee: LifeCell Corporation
    Inventors: Wenquan Sun, Nathaniel Bachrach, Mark Hayzlett
  • Patent number: 10350245
    Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: July 16, 2019
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Hans-Peter Kiem
  • Patent number: 10344076
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 9, 2019
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker
  • Patent number: 10335500
    Abstract: A major challenge in non-viral gene delivery remains finding a safe and effective delivery system. Colloidally stable non-viral gene vector delivery systems capable of overcoming various biological barriers, are disclosed. The gene vectors are biodegradable, non-toxic and highly tailorable for use in specific applications. The vectors include a mixture of biodegradable copolymers, such as PBAE, and biodegradable polymers conjugated with hydrophilic, neutrally charged polymer, such as PEG. The gene vectors demonstrate broad vector distribution and high transgene delivery in vivo, providing an efficient non-viral gene delivery system for localized therapeutic gene transfer. Methods of using the vectors to overcome biological barriers including mucus gel and extracellular matrix are provided. Methods of formulating the vectors are also provided.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: July 2, 2019
    Assignee: The Johns Hopkins University
    Inventors: Justin Hanes, Jung Soo Suk, Panagiotis Mastorakos
  • Patent number: 10322173
    Abstract: Problem To provide a chiral nucleic acid adjuvant and anti-allergic agent having anti-allergic effect. Solution An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: June 18, 2019
    Assignees: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., WAVE LIFE SCIENCES JAPAN, INC.
    Inventors: Takefumi Gemba, Ryoichi Nagata